INDIANAPOLIS, June 26 -- Pregabalin (Lyrica) just became the first medication approved by the FDA for fibromyalgia-related pain, but it may not work for everyone, so older treatments may still be useful.
In a pair of studies reported last month at the American Psychiatric Association meeting, the response rate varied from about 30% to 60%.
In November 2006, a preliminary report from one of those trials found that 63% of patients reported pain relief with the drug. (See ACR: Lyrica Shows Durable Effect In Fibromyalgia)
So the new drug probably won't make measures clinicians have relied on totally obsolete, Debra Bancroft Rizzo, M.S.N, FNP-C, of the Rheumatic Disease Center in Milwaukee, told attendees at the American Academy of Nurse Practitioners meeting here.
"Pregabalin was previously labeled for treating neuropathic pain associated with diabetic peripheral neuropathy and post-herpetic neuralgia as well as an add-on therapy for adults with partial onset seizures," she said.